Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sexuality and management of benign prostatic hyperplasia with alfuzosin 10mg once daily (Xatral OD 10mg), open, 24-week study.

Trial Profile

Sexuality and management of benign prostatic hyperplasia with alfuzosin 10mg once daily (Xatral OD 10mg), open, 24-week study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2009

At a glance

  • Drugs Alfuzosin (Primary)
  • Indications Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Acronyms SAMBA
  • Sponsors Sanofi
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Dec 2008 Planned number of patients changed from 425 to 431 as reported by ClinicalTrials.gov.
    • 08 Apr 2008 Status changed form in progress to completed, as reported in ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top